Efficacy of immune checkpoint inhibitors in different types of melanoma

Ernesto Rossia Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyCorrespondence[email protected]

https://orcid.org/0000-0002-6442-1707

Giovanni Schinzaria Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy

Brigida Anna Maioranob Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy

Giulia Indellicatia Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Alessandro Di Stefanic Dermatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome – Italy

Monica Maria Pagliarad Ophtalmology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Simona Maria Fragomenie Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Erika Valentina De Lucaf Institute of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy

Maria Grazia Sammarcod Ophtalmology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Giorgia Garganesee Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy;g Ginecology and Breast Care Center, Mater Olbia Hospital, Olbia, Italy

Jacopo Gallih Department of Head and Neck Surgery, Università Cattolica del Sacro Cuore, Rome, Italy

Maria Antonietta Blasid Ophtalmology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy;i Ophtalmology, Università Cattolica del Sacro Cuore, Rome, Italy

Gaetano Paludettih Department of Head and Neck Surgery, Università Cattolica del Sacro Cuore, Rome, Italy

Giovanni Scambiae Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy;j Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy

https://orcid.org/0000-0003-2758-1063

Ketty Perisc Dermatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome – Italy;f Institute of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy

Giampaolo Tortoraa Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy

show all

ABSTRACT

Immunotherapy can be used for cutaneous, mucosal, uveal and conjunctival melanoma. Nevertheless, we cannot expect the same benefit from checkpoint inhibitors for all the types of melanoma. The different biological features can explain the variable efficacy. The main results obtained with immune checkpoint inhibitors in the various types of melanoma were reviewed.

KEYWORDS:

Efficacy of immune checkpoint inhibitors in different types of melanoma

Information for

Open access

Opportunities

Help and information

Efficacy of immune checkpoint inhibitors in different types of melanoma

ABSTRACT

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature